MXPA04004164A - Analogos de omega-cicloalquil 17-heteroaril prostaglandina e2 como agonistas del receptor ep2. - Google Patents

Analogos de omega-cicloalquil 17-heteroaril prostaglandina e2 como agonistas del receptor ep2.

Info

Publication number
MXPA04004164A
MXPA04004164A MXPA04004164A MXPA04004164A MXPA04004164A MX PA04004164 A MXPA04004164 A MX PA04004164A MX PA04004164 A MXPA04004164 A MX PA04004164A MX PA04004164 A MXPA04004164 A MX PA04004164A MX PA04004164 A MXPA04004164 A MX PA04004164A
Authority
MX
Mexico
Prior art keywords
group
carbon atoms
bond
radical
hydrogen
Prior art date
Application number
MXPA04004164A
Other languages
English (en)
Inventor
F Posner Mari
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MXPA04004164A publication Critical patent/MXPA04004164A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4018—Esters of cycloaliphatic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere al uso de derivados de prostaglandinas tipo E como agonistas EP2, en general, y en particular, como hipotensivos oculares. Los derivados de PGE usados de conformidad con la invencion, estan representados por la formula (I): en donde el segmento sombreado representa un enlace a, el triangulo solido representa un enlace ??, el segmento ondulado representa enlaces a o ??, las lineas discontinuas representan un enlace doble o un enlace sencillo, X se selecciona del grupo que consiste de radicales de hidrogeno y halogeno, R3 es un radical heteroarilo o heteroarilo substituido, R1 y R2 se seleccionan independientemente del grupo que consiste de hidrogeno o un radial alquilo inferior que tiene hasta seis atomos de carbono, o un radical acilo inferior que tiene hasta seis atomos de carbono, r se selecciona del grupo que consiste de CO2R4, CONR42, CH2OR4, CONR4SO2R4, P (O) (OR4) y formula (II), EN DONDE R4 se selecciona del grupo que consiste de H, fenilo y alquilo inferior, que tienen de uno a seis atomos de carbono y n es 0 o un numero entero desde 1 hasta 4.
MXPA04004164A 2001-11-05 2002-10-25 Analogos de omega-cicloalquil 17-heteroaril prostaglandina e2 como agonistas del receptor ep2. MXPA04004164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33883801P 2001-11-05 2001-11-05
PCT/US2002/034301 WO2003040126A1 (en) 2001-11-05 2002-10-25 φ-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS

Publications (1)

Publication Number Publication Date
MXPA04004164A true MXPA04004164A (es) 2004-09-06

Family

ID=23326368

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004164A MXPA04004164A (es) 2001-11-05 2002-10-25 Analogos de omega-cicloalquil 17-heteroaril prostaglandina e2 como agonistas del receptor ep2.

Country Status (13)

Country Link
US (4) US6710072B2 (es)
EP (1) EP1442033B1 (es)
KR (1) KR20050039733A (es)
CN (1) CN1617868A (es)
AT (1) ATE305463T1 (es)
BR (1) BR0213911A (es)
CA (1) CA2466517A1 (es)
DE (1) DE60206408T2 (es)
ES (1) ES2246419T3 (es)
HK (1) HK1066801A1 (es)
MX (1) MXPA04004164A (es)
NZ (1) NZ532519A (es)
WO (1) WO2003040126A1 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875787B2 (en) * 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
GB0329620D0 (en) * 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
EP1812017A2 (en) * 2004-10-21 2007-08-01 Duke University Ophthamological drugs
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
DK1846354T3 (da) 2005-01-14 2010-08-16 Allergan Inc Substituterede cyclopentaner eller cyclopentanoner til behandling af okular hypertensive tilstande
EP1856042B1 (en) * 2005-03-10 2012-06-27 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7674786B2 (en) * 2005-05-06 2010-03-09 Allergan, Inc. Therapeutic β-lactams
ES2367920T3 (es) * 2005-05-06 2011-11-10 Allergan, Inc. Beta-lactamas sustituidas y su uso en medicina.
US8039507B2 (en) * 2005-06-29 2011-10-18 Allergan, Inc. Therapeutic substituted gamma lactams
CA2618486A1 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
US7427685B2 (en) 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2007109578A2 (en) * 2006-03-20 2007-09-27 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US7439372B2 (en) 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
US20090016981A1 (en) 2006-05-03 2009-01-15 Allergan, Inc. Therapeutic compounds
CA2660396A1 (en) * 2006-08-09 2008-02-21 Allergan, Inc. Therapeutic amides and related compounds
US7985767B2 (en) * 2006-09-06 2011-07-26 Allergan, Inc. Therapeutic amides
EP1903037A1 (de) * 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors
US8193373B2 (en) 2006-12-11 2012-06-05 Allergan, Inc. Therapeutic compounds
WO2008082217A1 (en) * 2006-12-28 2008-07-10 Lg Electronics Inc. Ice making system and method for ice making of refrigerator
JP5394933B2 (ja) * 2007-01-22 2014-01-22 アラーガン インコーポレイテッド 眼圧降下剤として有用なチオフェン誘導体
JP5453111B2 (ja) * 2007-01-22 2014-03-26 アラーガン インコーポレイテッド 治療薬としての置換アリールシクロペンタン類
WO2008094912A2 (en) * 2007-01-31 2008-08-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP2220057A4 (en) 2007-11-14 2011-10-12 Cayman Chem Co PROSTAGLANDIN E1 AND E2 ANALOGUES FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US7956051B2 (en) * 2008-01-24 2011-06-07 Allergan, Inc. Therapeutic amides and related compounds
US8633310B2 (en) * 2008-02-19 2014-01-21 Allergan, Inc. Therapeutic substituted lactams
WO2009111322A1 (en) * 2008-03-04 2009-09-11 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7964596B2 (en) * 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
US20090233921A1 (en) * 2008-03-11 2009-09-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US7960379B2 (en) * 2008-03-14 2011-06-14 Allergan, Inc. Therapeutic compounds
US7960378B2 (en) * 2008-03-18 2011-06-14 Allergan, Inc. Therapeutic compounds
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
US8198318B2 (en) * 2008-03-18 2012-06-12 Allergen, Inc. Therapeutic amides
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
US7956055B2 (en) * 2008-03-25 2011-06-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7803797B2 (en) * 2008-04-24 2010-09-28 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
CA2731279A1 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Therapeutic compounds
US7964634B2 (en) * 2008-04-24 2011-06-21 Allergan, Inc. Therapeutic compounds
WO2009132087A1 (en) 2008-04-24 2009-10-29 Allergan, Inc. Thiophene derivatives useful as ocular hypotensive agents
AU2009239369B2 (en) * 2008-04-24 2014-03-06 Allergan, Inc. Substituted arylcyclopentenes as prostaglandin EP2 agonists
BRPI0911347A2 (pt) 2008-04-24 2018-03-20 Allergan Inc gama lactamas substituídas como agentes terapêuticos
US7737140B2 (en) * 2008-04-24 2010-06-15 Allergan, Inc. Therapeutic compounds
AU2009239381A1 (en) 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7713967B2 (en) 2008-05-09 2010-05-11 Allergan, Inc. Therapeutic substituted hydantoins, and related compounds
WO2009137412A1 (en) * 2008-05-09 2009-11-12 Allergan, Inc. Therapeutic compounds
US8530471B2 (en) * 2008-05-09 2013-09-10 Allergan, Inc. Therapeutic cyclopentane derivatives
US7981887B2 (en) * 2008-05-09 2011-07-19 Allergan, Inc. Therapeutic compounds
JP2011520811A (ja) 2008-05-09 2011-07-21 アラーガン インコーポレイテッド 治療用の置換チアゾリジノン類、オキサゾリジノン類および関連化合物
BRPI0912193A2 (pt) * 2008-05-09 2015-10-06 Allergan Inc compostos terapêuticos.
CN102089285A (zh) * 2008-05-09 2011-06-08 阿勒根公司 治疗性的n-芳基或n-杂芳基吡唑烷和吡唑烷酮衍生物
EP2291346A2 (en) * 2008-05-15 2011-03-09 Allergan, Inc. Therapeutic substituted cyclopentanes
AU2009249388B2 (en) * 2008-05-20 2014-04-03 Allergan, Inc. Therapeutic lactams
CA2724605A1 (en) * 2008-05-27 2009-12-03 Allergan, Inc. Prostaglandin prodrugs as hypotensive agents
US7985765B2 (en) * 2008-08-20 2011-07-26 Allergan, Inc. Therapeutic substituted pyrroles
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US10100028B2 (en) 2013-09-30 2018-10-16 Patheon Api Services Inc. Synthesis routes for prostaglandins and prostaglandin intermediates using metathesis
US10105488B2 (en) 2013-12-12 2018-10-23 Medtronic Minimed, Inc. Predictive infusion device operations and related methods and systems

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
CA2221110C (en) * 1995-05-18 2009-08-04 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
JP2001139544A (ja) * 1999-11-12 2001-05-22 Taisho Pharmaceut Co Ltd プロスタグランジン誘導体
KR20030019628A (ko) * 2000-07-31 2003-03-06 오노 야꾸힝 고교 가부시키가이샤 프로스타글란딘 유도체를 유효 성분으로 하는 발기부전치료제
US6248783B1 (en) * 2000-09-20 2001-06-19 Allergan Sales, Inc. Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
US6376533B1 (en) * 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists

Also Published As

Publication number Publication date
US20040106580A1 (en) 2004-06-03
BR0213911A (pt) 2004-09-28
ES2246419T3 (es) 2006-02-16
HK1066801A1 (en) 2005-04-01
CA2466517A1 (en) 2003-05-15
CN1617868A (zh) 2005-05-18
EP1442033B1 (en) 2005-09-28
ATE305463T1 (de) 2005-10-15
US6710072B2 (en) 2004-03-23
US20030130239A1 (en) 2003-07-10
US7022726B2 (en) 2006-04-04
NZ532519A (en) 2006-11-30
DE60206408D1 (de) 2006-02-09
KR20050039733A (ko) 2005-04-29
US20070219262A1 (en) 2007-09-20
DE60206408T2 (de) 2006-06-22
WO2003040126A1 (en) 2003-05-15
EP1442033A1 (en) 2004-08-04
US20050113338A1 (en) 2005-05-26
US7223746B2 (en) 2007-05-29
US7514462B2 (en) 2009-04-07

Similar Documents

Publication Publication Date Title
MXPA04004164A (es) Analogos de omega-cicloalquil 17-heteroaril prostaglandina e2 como agonistas del receptor ep2.
DK1563032T3 (da) Sammensætninger, der indeholder floursubstituerede olefiner
DK0783486T3 (da) Hidtil ukendte prostaglandinsynthaseinhibitorer
CA2221110A1 (en) Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
DE69828284D1 (de) Naphthyridinderivate oder salze davon
DK1390036T3 (da) Prostansyrederivater som midler til nedsættelse af intraokulært tryk
FI812804L (fi) 2-(1,4-bensodioxan-2-ylalkyl)-imidazoler anvaendbara som antidepressiva laekemedel
ES8601897A1 (es) Un metodo de preparar derivados de 4-quinolona
DE502004002035D1 (de) Acetale, ihre verwendung als riechstoffe und verfahren zu ihrer herstellung
SE9002596D0 (sv) A method for synthesis of prostaglandin derivatives
JO2433B1 (en) Preparation of heterocyclic lindane landscapes
MEP12408A (en) Acyloxypyrrolidine derivatives and use thereof as ligands of v1b or both v1b and v1a receptors
ES2182523T3 (es) Derivados de indolilo como agentes serotonergicos.
HUP0300391A2 (hu) Prosztaglandinnal rokon vegyületek alkalmazása szemen belüli túlnyomás és glaukóma kezelésére alkalmas készítmény előállítására
DE69011714D1 (de) Kalziumantagonisten.
HRP20030712B1 (en) Caloporoside derivatives, methods for the production thereof and their use
DE50211559D1 (en) Hydrophilieadditive
US4366313A (en) 2-Decarboxy-2-tetrazolyl-6-keto-PGE1 compounds
US4257983A (en) 2-Decarboxy-2-aminomethyl-19,20-didehydro-PG1 compounds
US4257982A (en) 2-Decarboxy-2-aminomethyl-19,20-didehydro-13,14-dihydro-PG2 compounds
US4264524A (en) 19,20-Didehydro-PG1 amides
US4264523A (en) 19,20-Didehydro-13,14-dihydro-PG1 amides
US4336392A (en) 2-Decarboxy-2-tetrazolyl-PG1 compounds
ES2088289T3 (es) Derivados de androst-4-eno(4,5-b)pirrol y su procedimiento de preparacion.
CO4940468A1 (es) Nuevos derivados de naftilpiperacina

Legal Events

Date Code Title Description
FG Grant or registration